Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Digital Health Trends 2024 - Implications for Research and Patient Care

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
White Paper
National Ownership of Antibiotic Access and Use: Driving Policy Decision-Making Based on Population Needs
Sep 25, 2024
  • Locations
  • EMEA
  • Library
  • National Ownership of Antibiotic Access and Use: Driving Policy Decision-Making Based on Population Needs

Get instant access

Download

This paper discusses the development of national antibiotic assessment reports (NAARs) as foundations for the design of national antibiotic policies. It proposes that more robust national data on antibiotic use that integrates population health factors can support equitable access to these medicines and inform global targets. Overall, a better and more accurate understanding of antibiotic use can increase national ownership and curb the impact of antimicrobial resistance (AMR).

Antimicrobial resistance (AMR) is one of the most pressing global public health threats today. As microorganisms evolve and no longer respond to available treatments, the options for managing and preventing severe infections become limited. This not only increases the risk of complications, hospital admissions, and death but also threatens advances in medical care. Recent outbreaks and pandemics have further underscored the far-reaching consequences of infectious diseases without effective treatment, raising critical questions about preparedness and global coordinated action.

To address these challenges, the World Health Organization (WHO) has systematically provided guidance and tools to support countries in combating AMR. Such efforts include global targets, stewardship protocols, and parameters for national action plans (NAPs). However, current trends in antibiotic use and the rising deaths attributed to bacterial resistance, estimated at 4.95 million in 2019, suggest the need for different approaches.

This white paper discusses the development of national antibiotic assessment reports (NAARs) as foundations for designing national antibiotic policies. By using a single standard method to combine multiple antibiotic use datasets within these reports, information can be made comparable within and across countries. Therefore, creating a more comprehensive assessment of antibiotic use, factoring in population health factors, could increase national ownership and improve the AMR response.

The paper is divided into three parts:

  1. Understanding antibiotic use in humans: This section discusses global trends in antibiotic use over the last decade, reflects on current efforts and challenges to develop new anti-infectives, and highlights the barriers to collecting and processing the right data on AMR. An analysis of IQVIA data covering pharmacy sales in 87 countries from 2013 to 2023 shows an increase in antibiotic use worldwide, with noticeable variations across regions. The antibiotics selected for review are representative of the Access, Watch, and Reserve (AWaRe) groups, a WHO classification set in 2017 to support surveillance and ensure appropriate use and long-term stewardship.
  2. The need for standardized NAARs: This section delves into the need for detailed antibiotic use assessments, including metrics to better inform national antibiotic policies and monitor progress. It presents an analysis of gaps in current NAPs and emphasizes the importance of comprehensive data collection and responsible antibiotic use. The paper proposes that more robust global and national data on antibiotic use can streamline procurement and financial decisions and, in turn, support equitable access to these medicines.
  3. Partnership frameworks as catalysts for NAARs and national antibiotic policies: The final section elaborates on the partnership frameworks required to formulate NAARs and national antibiotic policies. It discusses the potential integration of multi-disciplinary technical capabilities across key stakeholders to better monitor antibiotic use and the trajectory of AMR.

By providing a comprehensive assessment of antibiotic use and proposing robust data collection methods, this paper ultimately aims to support the development of effective national antibiotic policies and optimize the global response to AMR.

Contact Us